期刊文献+

TRAIL联合多西紫杉醇诱导喉鳞癌Hep-2细胞凋亡的实验研究

Effects of TRAIL and Docetaxel on Cellular Apoptosis of Human Laryngeal Squamous Carcinoma Cells
原文传递
导出
摘要 目的:观察肿瘤坏死因子相关凋亡诱导配体(TRAIL)联合多西紫杉醇应用于人喉鳞癌Hep-2细胞生长的抑制增殖和诱导凋亡作用。方法:实验分四组,1组对照组,2组为应用TRAIL组,3组单独应用多西紫杉醇,4组联合应用TRAIL及多西紫杉醇。分别应用MTT、流式细胞仪检测细胞凋亡率,倒置显微镜观察细胞的形态学改变。结果:TRAIL与多西紫杉醇联合作用于Hep-2细胞,能显著增强对Hep-2细胞的杀伤、抑制增殖及诱导凋亡作用,其联合应用的凋亡抑制率明显高于单独应用TRAIL组和多西紫杉醇组(P<0.05)。结论:TRAIL与多西紫杉醇联用能显著提高对喉鳞癌Hep-2细胞的生长抑制和诱导凋亡作用。 Objeelive: To investigate the apoptosis inducing effect by tumor necrosis factor related apoptosis-ligand(TRAIL)and docetaxel on human laryngeal squarnous carcinoma Hep-2 cells. Methods: Four groups were divided to conduct the experiment: Group 1 as control group, TRAIL applied to Group 2, docetaxel applied to Group 3, and TRAIL combined with docetaxel for Group 4.Apoptosis rate was detected by using MTT and FCM, and mophological changes were observed with inverted microscope. Results: TRAIL and docetaxel combination in Hep 2 cells, can significantly enhance the Hep-2 cells of destruction, inhibit proliferation and induce apoptosis, apoptosis inhibition rate of the joint application was obviously higher than that of single application of TRAIL and docetaxel group (P〈0. 05). Conclusion" The combination of TRAIL and doeetaxel could significantly increase apoptosis effects on human laryngeal squamous carcinoma cells.
出处 《现代生物医学进展》 CAS 2014年第19期3619-3621,3630,共4页 Progress in Modern Biomedicine
基金 黑龙江省教育厅科学技术研究项目(11541177)
  • 相关文献

参考文献9

  • 1毛淑华,于水静,晏菊芳,姬玲玲,黄英.5-Fu与TRAIL联用抗结肠癌细胞株HT-29效应的实验研究[J].华西药学杂志,2010,25(5):564-566. 被引量:1
  • 2Kazuya Kuraoka,Shunji Matsumura,Yuichi Sanada,Kei Nakachi,Kazue Imai,Hidetaka Eguchi,Keisuke Matsusaki,Naohide Oue,Hirofumi Nakayama,Wataru Yasui.A single nucleotide polymorphism in the extracellular domain of TRAILreceptor DR4 at nucleotide 626 in gastric cancer patients in Japan[J].Oncology Reports.2005(2) 被引量:1
  • 3Liqing Zhuang,C. Soon Lee,Richard A. Scolyer,Stanley W. McCarthy,Xu Dong Zhang,John F. Thompson,Gavin Screaton,Peter Hersey.Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor–related apoptosis-inducing ligand[J].Human Pathology.2006(10) 被引量:1
  • 4Takenari Yamanaka,Katsuya Shiraki,Kazushi Sugimoto,Takeshi Ito,Katsuhiko Fujikawa,Masaaki Ito,Koujiro Takase,Masami Moriyama,Takeshi Nakano,Atsushi Suzuki.Chemotherapeutic Agents Augment TRAIL-Induced Apoptosis in Human Hepatocellular Carcinoma Cell Lines[J].Hepatology.2000(3) 被引量:1
  • 5Frank A.E. Kruyt.TRAIL and cancer therapy[J].Cancer Letters.2008(1) 被引量:1
  • 6Dae-Hee Lee,Chang Sup Lee,Dong-Wook Kim,Jeh Eun Ae,Tae-Hwa Lee.Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin[J].Anti-Cancer Drugs.2014(1) 被引量:1
  • 7姚鸿超,肖辉,李茗华,王超,刘鸣.TRAIL联合多西紫杉醇对人鼻咽癌CNE2细胞的体外作用研究[J].现代生物医学进展,2010,10(6):1058-1060. 被引量:4
  • 8Paul E. Carrington,Cristinel Sandu,Yufeng Wei,Justine M. Hill,Gaku Morisawa,Ted Huang,Evridipis Gavathiotis,Yu Wei,Milton H. Werner.The Structure of FADD and Its Mode of Interaction with Procaspase-8[J].Molecular Cell.2006(5) 被引量:1
  • 9E.W. Duiker,C.H. Mom,S. de Jong,P.H.B. Willemse,J.A. Gietema,A.G.J. van der Zee,E.G.E. de Vries.The clinical trail of TRAIL[J].European Journal of Cancer.2006(14) 被引量:1

二级参考文献6

  • 1Wiley SR, Schooley K, Smolack P J, et al. Idantifieation and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity, 1995, 3:673-682. 被引量:1
  • 2Law rence D, Shahrokh Z, Marsters S, et al. D ifferentiai hepatoeyte toxicity ofrecom binant Apo2L/TRAIL versions [J]. Nat Med, 2001, 7:383-385. 被引量:1
  • 3Yamanaka T, Shimki K, Sugimoto K, et al, Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatoceUular carcinoma cell lines[J]. Hepatology, 2000, 32:482-490. 被引量:1
  • 4Mitsiades N, Poulaki V, Sophia TB, et al. Thyroid carcinoma cells are resistant to FAS-mediatedd apoptosis but sensitibe to tumor necrosis factor-related apoptosis-inducing ligand [J]. Cancer research, 2000, 60:4122-4129. 被引量:1
  • 5Tanaka S, Sugimachi K, Shirabe K, et al. Expression and antitumor effecs of TRAIL in human cholangiocarcinoma [J]. Hepatoiogy, 2000, 32:523-527. 被引量:1
  • 6Ronald Koschny,Henning Walczak,Tom M. Ganten. The promise of TRAIL—potential and risks of a novel anticancer therapy[J] 2007,Journal of Molecular Medicine(9):923~935 被引量:1

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部